Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine

被引:36
作者
Tempone, Andre Gustavo [1 ]
Taniwaki, Noemi Nosomi [1 ]
Reimao, Juliana Quero [1 ]
机构
[1] Adolfo Lutz Inst, Lab Toxinol Aplicada, Dept Parasitol, BR-01246000 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
CONTROLLED TRIAL; NITRIC-OXIDE; IN-VITRO; DONOVANI; MACROPHAGES; LACIDIPINE; DISEASE; 1,4-DIHYDROPYRIDINES; DERIVATIVES; LIGANDS;
D O I
10.1007/s00436-009-1427-8
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
In a search for novel antileishmanial drugs, we investigated the activity of the calcium channel blocker nimodipine against Leishmania spp. and explored the ultrastructural damages of parasites induced by nimodipine after a short period of incubation. Nimodipine was highly effective against promastigotes and intracellular amastigotes of Leishmania (L.) chagasi, with 50% inhibitory concentration values of 81.2 and 21.5 mu M, respectively. Nimodipine was about fourfold more effective than the standard pentavalent antimony against amastigotes and showed a Selectivity Index of 4.4 considering its mammalian cells toxicity. Leishmania (L.) amazonensis and Leishmania (L.) major promastigotes were also susceptible to nimodipine in a range concentration between 31 and 128 mu M. Ultrastructural studies of L. (L.) chagasi revealed intense mitochondria damage and plasma membrane blebbing, resulting in a leishmanicidal effect as demonstrated by the lack of mitochondrial oxidative metabolism. The amastigote-killing effect suggests other mechanism than macrophage activation, as no upregulation of nitric oxide was seen. This calcium channel blocker is an effective in vitro antileishmanial compound and if adequately studied could be used as a novel drug candidate or as a novel drug lead compound for drug design studies against leishmaniasis.
引用
收藏
页码:499 / 505
页数:7
相关论文
共 32 条
[1]   CEREBRAL ARTERIAL SPASM - A CONTROLLED TRIAL OF NIMODIPINE IN PATIENTS WITH SUBARACHNOID HEMORRHAGE [J].
ALLEN, GS ;
AHN, HS ;
PREZIOSI, TJ ;
BATTYE, R ;
BOONE, SC ;
CHOU, SN ;
KELLY, DL ;
WEIR, BK ;
CRABBE, RA ;
LAVIK, PJ ;
ROSENBLOOM, SB ;
DORSEY, FC ;
INGRAM, CR ;
MELLITS, DE ;
BERTSCH, LA ;
BOISVERT, DPJ ;
HUNDLEY, MB ;
JOHNSON, RK ;
STROM, JA ;
TRANSOU, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (11) :619-624
[2]   Leishmania donovani induces interferon regulatory factor in murine macrophages:: a host defense response [J].
Balaraman, S ;
Tewary, P ;
Singh, VK ;
Madhubala, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 317 (02) :639-647
[3]  
Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1768-1797.2006, 10.1128/AAC.50.5.1788-1797.2006]
[4]   Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia [J].
Blardi, P ;
Urso, R ;
de Lalla, A ;
Volpi, L ;
Di Perri, T ;
Auteri, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :556-561
[5]   Drug resistance in leishmaniasis [J].
Croft, SL ;
Sundar, S ;
Fairlamb, AH .
CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (01) :111-+
[6]   Public-private partnership: from there to here [J].
Croft, SL .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2005, 99 :S9-S14
[7]  
Dasgupta A, 2007, IN VIVO, V21, P847
[8]   Leishmaniasis: new approaches to disease control [J].
Davies, CR ;
Kaye, P ;
Croft, SL ;
Sundar, S .
BRITISH MEDICAL JOURNAL, 2003, 326 (7385) :377-382
[9]   Synthesis and antitumour evaluation of peptidyl-like derivatives containing the 1,3-benzodioxole system [J].
de Magalhaes Moreira, Diogo Rodrigo ;
Lima Leite, Ana Cristina ;
Pirtheiro Ferreira, Paulo Michel ;
da Costa, Patricia Marcal ;
Costa Lotufo, Leticia Veras ;
de Moraes, Manoel Odorico ;
Brondani, Dalci Jose ;
Pessoa, Claudia do O. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2007, 42 (03) :351-357
[10]  
DUARTE MIS, 1992, ULTRASTRUCT PATHOL, V16, P475